Literature DB >> 2556314

Cytotoxic activities of a fusion protein comprised of TGF alpha and Pseudomonas exotoxin.

C B Siegall1, Y H Xu, V K Chaudhary, S Adhya, D Fitzgerald, I Pastan.   

Abstract

A cDNA encoding transforming growth factor type alpha (TGF alpha) was fused to the 5' end of a gene encoding a modified form of Pseudomonas exotoxin A (PE), which is devoid of the cell recognition domain (domain Ia). The chimeric molecule, termed TGF alpha-PE40, was expressed in Escherichia coli and isolated from the periplasm or inclusion bodies depending on the construction expressed. TGF alpha-PE40 was found to be extremely cytotoxic to cells displaying epidermal growth factor (EGF) receptors. Comparison with a similar molecule in which TGF alpha was placed at the carboxyl end of PE40 demonstrated the importance of the position of the cell recognition element; TGF alpha-PE40 was found to be about 30-fold more cytotoxic to cells bearing EGF receptors than PE40-TGF alpha. In addition, TGF alpha-PE40 was shown to be extremely cytotoxic to a variety of cancer cell lines including liver, ovarian, and colon cancer cell lines, indicating high levels of EGF receptor expression in these cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2556314     DOI: 10.1096/fasebj.3.14.2556314

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.834


  17 in total

Review 1.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

Review 2.  Fibroblasts are critical determinants in prostatic cancer growth and dissemination.

Authors:  L W Chung
Journal:  Cancer Metastasis Rev       Date:  1991-10       Impact factor: 9.264

3.  A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins.

Authors:  V K Chaudhary; J K Batra; M G Gallo; M C Willingham; D J FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

4.  Interferon alpha2 recombinant and epidermal growth factor modulate proliferation and hypusine synthesis in human epidermoid cancer KB cells.

Authors:  M Caraglia; A Passeggio; S Beninati; A Leardi; L Nicolini; S Improta; A Pinto; A R Bianco; P Tagliaferri; A Abbruzzese
Journal:  Biochem J       Date:  1997-06-15       Impact factor: 3.857

Review 5.  EGFR(s) in aging and carcinogenesis of the gastrointestinal tract.

Authors:  Jyoti Nautiyal; Shailender Singh Kanwar; Adhip P N Majumdar
Journal:  Curr Protein Pept Sci       Date:  2010-09       Impact factor: 3.272

6.  Activity of a recombinant transforming growth factor-alpha-Pseudomonas exotoxin hybrid protein against primary human tumor colony-forming units.

Authors:  D D Von Hoff; M H Marshall; D C Heimbrook; S M Stirdivant; J D Ahern; W K Herbert; R Z Maigetter; A Oliff
Journal:  Invest New Drugs       Date:  1992-04       Impact factor: 3.850

Review 7.  Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer.

Authors:  Dennis J Yoon; Christina T Liu; Devin S Quinlan; Parsa M Nafisi; Daniel T Kamei
Journal:  Ann Biomed Eng       Date:  2011-02-25       Impact factor: 3.934

8.  Enhancement of cell type specificity by quantitative modulation of a chimeric ligand.

Authors:  Pablo Cironi; Ian A Swinburne; Pamela A Silver
Journal:  J Biol Chem       Date:  2008-01-29       Impact factor: 5.157

9.  Substitution of foreign protein sequences into a chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin.

Authors:  W Debinski; C B Siegall; D Fitzgerald; I Pastan
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 5.069

10.  Transforming growth factor alpha-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts.

Authors:  D C Heimbrook; S M Stirdivant; J D Ahern; N L Balishin; D R Patrick; G M Edwards; D Defeo-Jones; D J FitzGerald; I Pastan; A Oliff
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 12.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.